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Background
In Europe Etanercept is licensed for the treatment of resist-
ant polyarticular JIA at a dosage of 0.4 mg/kg bw. twice
weekly in children older than 4 years.
Objectives
To evaluate the safety and efficacy of Etanercept once
weekly 0.8 mg/kg up to 50 mg in a formal trial.
Methods
At each study site an independent ethics committee
approved the protocol, and each patient's parent gave
written informed consent (EudraCT No. 2007-000255-
34). 20 patients 4 to 17 years old were included and
received 0.8 mg/kg bw. of etanercept subcutaneously once
weekly for 12 weeks "Active" polyarticular disease was
defined by the presence of five or more active joints.
PedACR30/50/70 criteria were calculated.
Safety assessments were based on adverse events (AE)
reported.
Results
15 of 20 JIA patients, 16 girls and 4 boys, mean age 12.9
years, disease duration 4.1 years, already have completed
the 12 week study period. The mean dosage was 0.80 +/-
0.04 mg/kg Etanercept. Concomitant treatments were
kept stable 3 months before and throughout the study and
consisted of NSAID (n = 20), prednisone (n = 4), meth-
otrexate (n = 12), leflunomide (n = 2), sulfsalazine (n =
1). A PedACR 30/50/70 response was reached by 73%/
26%/10% of patients after 4 weeks, 86%/73%/40% after
8 weeks and 92%/92%/79% after 12 weeks of treatment.
There were 33 AEs but no SAE: 9 minor infections 12
injection site reactions and 12 other AEs. There was no
drop out.
Conclusion
These data indicate that once weekly application of
Etanercept at double dosage of 0.8 mg/kg bodyweight up
to 50 mg per injection is safe and efficacious in polyartic-
ular JIA patients.
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